FGF21
Fibroblast growth factor, (FGF21) is a multifaceted protein encoded by the FGF21 gene and classified within the fibroblast growth factor family. It is primarily produced in the liver and acts as a hormone, influencing various metabolic processes. FGF21 gene therapy has significant implications for metabolic regulation, dietary behavior, and therapeutic applications in treating obesity and related metabolic disorders.
FGF21 plays a crucial role in regulating glucose by enhancing glucose uptake in adipocytes with promoting insulin sensitivity. It positively affects lipid metabolism and can lower plasma levels of triglycerides and cholesterol.
The metabolic regulation starts in the brain with FGF21 attaching to the receptors in the hypothalamus. Here it affects dopamine neurotransmission. It acts on the brain to modulate sugar intake and preferences for sweet foods. The expression of FGF21 is induced under conditions of metabolic stress, such as low protein intake or caloric restriction. FGF21also promotes weight loss by enhancing energy expenditure and altering the metabolic profile of adipose tissue.
FGF21 has garnered attention for its potential use in treating metabolic diseases such as obesity and diabetes. Animal studies have shown that FGF21 administration can reduce blood glucose and triglyceride levels, improve insulin sensitivity, and promote weight loss.
EFFECTS
- It is a major metabolic regulator
- Reduces non-HDL and lipoprotein A
- Increases insulin sensitivity
- Plays a significant role in glucose metabolism
- Promotes weight loss
- Improves aspects of obesity
- Improves aspects of diabetes
- Regulates many aspects of aging
Supporting Scientific Literature
Here are summaries of articles with text links regarding Fibroblast Growth Factor 21 (FGF21) published in the literature:
Bibliometric Analysis of FGF21 Research – a comprehensive bibliometric analysis of FGF21 research over the last two decades. It identifies trends, key contributors, and core topics in the field. The analysis revealed 2,490 publications, with significant contributions from the USA. Major research areas include FGF21’s physiological roles, clinical applications, and drug development.
https://doi.org/10.3389%2Ffphar.2022.1011008
FGF21 as Modulator of Metabolism in Health and Disease – discusses FGF21 as a crucial hormone regulating metabolic pathways. It highlights its expression in various tissues, including skeletal muscle, and its role in adapting to physiological and pathological conditions such as exercise and mitochondrial dysfunction.
https://doi.org/10.3389/fphys.2019.00419
Advances in Biological Functions and Clinical Studies of FGF21- reviews the expanding understanding of FGF21’s biological functions, including its metabolic regulation, protective roles in injury, and implications in various diseases. It discusses FGF21’s effects on blood sugar and lipid levels, obesity, and cardiovascular health, as well as its potential in reducing inflammation and oxidative stress. The authors suggest that FGF21 has promising therapeutic prospects in treating metabolic disorders and related conditions.
doi: 10.2147/DMSO.S317096
FGF21’s Role in Metabolic Regulation – details the discovery of FGF21 as a metabolic regulator and its effects on glucose and lipid metabolism. It discusses FGF21’s role in adaptive responses to starvation, including ketogenesis and lipolysis, and its expression in various tissues. The research indicates that FGF21 is a key player in metabolic adaptation during fasting and may serve as a therapeutic target for metabolic diseases.
https://doi.org/10.3389/fphys.2019.00419
Fibroblast growth factor 21 prolongs lifespan and improves stress tolerance in silkworms – This study used the silkworm, Bombyx mori, as an experimental model to evaluate the effects of exogenous FGF21 administration on lifespan and stress tolerance. The results showed that FGF21 replenishment significantly prolonged lifespan in female silkworms and enhanced stress resistance, including UV irradiation tolerance and thermotolerance. FGF21 activated AMPK, FoxO, and sirtuins, which may be responsible for the observed longevity and stress tolerance benefits.
Long-term effects of a fat-directed FGF21 gene therapy in aged mice – This study investigated whether long-term FGF21 gene transfer could mitigate aging-related functional decline in 17-month-old female mice. A single dose of fat-directed AAV-FGF21 treatment provided a sustainable, high serum level of FGF21 over a long period of time. The treatment reduced adiposity, increased relative lean mass and energy expenditure, but did not improve liver or muscle functions in aged mice.
DOI: 10.1038/s41434-023-00422-0
The starvation hormone, fibroblast growth factor-21, extends lifespan in mice – Transgenic overexpression of FGF21 markedly extended lifespan in mice without reducing food intake or affecting markers of NAD+ metabolism or AMP kinase and mTOR signaling. Transcriptomic analysis suggested that FGF21 acts primarily by blunting the growth hormone/insulin-like growth factor-1 signaling pathway in the liver.
https://doi.org/10.7554/eLife.00065
Results: notable reduction in non-HDL and total cholesterol, improved lipid risk profile, improved glucose sensitivity.